organization · Reporting owner
Atlas Venture Fund X, L.P.
Disclosed activity across 8 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImageneBio, Inc.IKNA · Entity 7139 | 10% owner | March 30, 2021 | April 01, 2021 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | 10% owner | March 11, 2024 | March 13, 2024 |
| Q32 Bio Inc.QTTB · Entity 5594 | 10% owner | March 25, 2024 | March 27, 2024 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | 10% owner | July 19, 2019 | July 30, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImageneBio, Inc.
Report date March 30, 2021 · Filed April 01, 2021
Jointly reported with ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,901,609 |
Reported balance
After 2021-03-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-03-30 · Conversion · Acquired 2,901,609 · Balance 2,901,609 F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,268,213 |
Reported balance
After 2021-03-30 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-03-30 · Conversion · Acquired 1,099,118 · Balance 1,268,213 F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("Associates XI") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("Associates XI LLC") is the general partner of Associates XI. Each of Associates XI and Associates XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas XI, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 749,634 |
Reported balance
After 2021-03-30 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-03-30 · Conversion · Acquired 749,634 · Balance 749,634 F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F4: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-03-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-30 · Conversion · Disposed 9,499,999 · Balance 0 F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-03-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-30 · Conversion · Disposed 11,258,117 · Balance 0 F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-03-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-30 · Conversion · Disposed 7,863,094 · Balance 0 F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("Associates XI") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("Associates XI LLC") is the general partner of Associates XI. Each of Associates XI and Associates XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas XI, except to the extent of its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2021-03-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-30 · Conversion · Disposed 5,362,888 · Balance 0 F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F4: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.
F3: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("Associates XI") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("Associates XI LLC") is the general partner of Associates XI. Each of Associates XI and Associates XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas XI, except to the extent of its pecuniary interest therein, if any.
F4: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.
Kymera Therapeutics, Inc.
Report date March 11, 2024 · Filed March 13, 2024
Jointly reported with ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,676,075 |
Last balance in matching sequence
After 2024-03-13 transaction · row 10
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2024-03-11 · Sale · Disposed 37,180 · Balance 4,930,934 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10). F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Row 2 · 2024-03-11 · Sale · Disposed 5,122 · Balance 4,925,812 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive. F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Row 5 · 2024-03-12 · Sale · Disposed 126,066 · Balance 4,799,746 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive. F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Row 6 · 2024-03-12 · Sale · Disposed 8,581 · Balance 4,791,165 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive. F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Row 9 · 2024-03-13 · Sale · Disposed 108,404 · Balance 4,682,761 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive. F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Row 10 · 2024-03-13 · Sale · Disposed 6,686 · Balance 4,676,075 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive. F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 828,830 |
Last balance in matching sequence
After 2024-03-13 transaction · row 12
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 3 · 2024-03-11 · Sale · Disposed 7,837 · Balance 882,311 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10). F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Row 4 · 2024-03-11 · Sale · Disposed 1,045 · Balance 881,266 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive. F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Row 7 · 2024-03-12 · Sale · Disposed 26,452 · Balance 854,814 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive. F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Row 8 · 2024-03-12 · Sale · Disposed 1,819 · Balance 852,995 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive. F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Row 11 · 2024-03-13 · Sale · Disposed 22,779 · Balance 830,216 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive. F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Row 12 · 2024-03-13 · Sale · Disposed 1,386 · Balance 828,830 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive. F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.1826 to $43.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7), (8), (9) and (10).
F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.185 to $44.03 inclusive.
F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.
F6: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.445 to $42.43 inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.46 to $42.90 inclusive.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.50 to $42.475 inclusive.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6032 to $43.0839 inclusive.
Q32 Bio Inc.
Report date March 25, 2024 · Filed March 27, 2024
Jointly reported with ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 864,261 |
Reported balance
Holding disclosure · report date 2024-03-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 864,261 F1: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Atlas Venture Opportunity Fund I, L.P. | 503,296 |
Reported balance
Holding disclosure · report date 2024-03-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 503,296 F2: Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Atlas Venture Opportunity Fund II, L.P. | 724,549 |
Reported balance
Holding disclosure · report date 2024-03-25 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 724,549 F3: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
F2: Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
F3: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
Tectonic Therapeutic, Inc.
Report date July 19, 2019 · Filed July 30, 2019 · Amendment
Jointly reported with ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,756,478 |
Reported balance
Holding disclosure · report date 2019-07-19 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 4,756,478 F1: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dianthus Therapeutics, Inc. /DE/
Report date February 11, 2021 · Filed February 16, 2021
Section 16 reporting ended · disclosed 2021-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,148,399 |
Reported balance
After 2021-02-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-02-11 · Other · Disposed 968,726 · Balance 3,148,399 F1: Represent a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("AVF X") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted in accordance with Rule 10b5-1 on September 25, 2020. F2: The shares are held directly by AVF X. The general partner of AVF X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVF X, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("AVF X") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted in accordance with Rule 10b5-1 on September 25, 2020.
F2: The shares are held directly by AVF X. The general partner of AVF X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVF X, except to the extent of its pecuniary interest therein, if any.
Disc Medicine, Inc.
Report date January 23, 2024 · Filed January 25, 2024
Jointly reported with ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Section 16 reporting ended · disclosed 2024-01-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,402,186 |
Reported balance
After 2024-01-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-01-23 · Sale · Disposed 47,500 · Balance 1,402,186 F1: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 703,660 |
Reported balance
After 2024-01-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-01-23 · Sale · Disposed 82,500 · Balance 703,660 F2: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 198,326 |
Reported balance
After 2024-01-23 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-01-23 · Sale · Disposed 20,000 · Balance 198,326 F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.
F2: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.
F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any.
Generation Bio Co.
Report date February 09, 2026 · Filed February 09, 2026
Jointly reported with ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC
Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-02-09 · Other · Disposed 711,193 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F3: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2026-02-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-02-09 · Other · Disposed 116,693 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, LP ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2026-02-09 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-02-09 · Other · Disposed 60 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F5: The shares are held directly by AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVAO I LP except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),
F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F3: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any.
F4: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, LP ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.
F5: The shares are held directly by AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVAO I LP except to the extent of its pecuniary interest therein, if any.
Replimune Group, Inc.
Report date September 15, 2020 · Filed September 17, 2020
Section 16 reporting ended · disclosed 2020-09-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,486,296 |
Reported balance
After 2020-09-15 transaction · row 1
1 source rowRow 1 · 2020-09-15 · Other · Disposed 445,339 · Balance 2,486,296 F1: Represent a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted in accordance with Rule 10b5-1 on February 28, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted in accordance with Rule 10b5-1 on February 28, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2020 Filed Aug 25, 2020 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | ConversionSeries Seed Convertible Preferred Stock · Derivative | 3,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023368 · doc4.xml · derivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,880,995 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 25, 2020 Filed Aug 25, 2020 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | ConversionCommon Stock | 1,112,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023368 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,112,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Dr. Booth is a member of AVAO LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 25, 2020 Filed Aug 25, 2020 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | ConversionCommon Stock | 7,196,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023368 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,948,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of common stock received upon the conversion of the Issuer's preferred stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a one-for-1.5949 basis upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 22:54 UTC | Replimune Group, Inc. REPL · Entity 4707 | OtherCommon Stock | 445,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041517 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,931,635 F1 · kind: Represent a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted in accordance with Rule 10b5-1 on February 28, 2020. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:28 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionSeries C Preferred Stock · Derivative | 268,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017100 · doc4.xml · derivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,518,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.exercise_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.expiration_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I. The general partner of Atlas Venture Opportunity Fund I is AVAO I LP. AVAO I LLC is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:28 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionSeries A Preferred Stock · Derivative | 15,051,020 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017100 · doc4.xml · derivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 8,521,213 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 16, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On June 16, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On June 16, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is AVA X LP. AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:28 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionCommon Stock | 10,040,032 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017100 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,630,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On June 16, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: Includes 11,111,939 shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X") and 1,518,819 shares held by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:37 UTC | Replimune Group, Inc. REPL · Entity 4707 | OtherCommon Stock | 445,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037603 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,376,974 F1 · kind: Represent a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted in accordance with Rule 10b5-1 on February 28, 2020. Read SEC document |
| July 19, 2019 Filed Jul 23, 2019 20:09 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | PurchaseCommon Stock | 810,811 | $18.50 | $15,000,003.50 |
DisclosureSEC source: 0000899243-19-020101 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,567,289 F1 · ownership.nature: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 14,245 | $17.86 | $254,415.70 |
DisclosureSEC source: 0001209191-19-021017 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold by AVA X LP in multiple transactions at prices ranging from $17.75 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | OtherCommon Stock | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021017 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,245 F3 · kind: Represents the shares received by AVA X LP in connection with the pro rata distribution described in footnote 1 by AVF X. F4 · ownership.nature: The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 21:03 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | OtherCommon Stock | 726,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021017 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,117,125 F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("AVF X") to its general partner and limited partners without additional consideration. F2 · ownership.direct: The shares are held directly by AVF X. The general partner of AVF X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVF X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | OtherCommon Stock | 631,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010172 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,822,313 F1 · kind: Represent a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted in accordance with Rule 10b5-1 on August 22, 2018. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:25 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,013,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047457 · a4.xml · derivative · entry 4 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,013,547 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F3 · shares: Reflects the number of shares of Preferred Stock held by the Reporting Person on an as-converted to common stock basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F3 · derivative.underlying_shares: Reflects the number of shares of Preferred Stock held by the Reporting Person on an as-converted to common stock basis. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:25 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionSeries A Convertible Preferred Stock · Derivative | 3,439,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-047457 · a4.xml · derivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,439,839 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F3 · shares: Reflects the number of shares of Preferred Stock held by the Reporting Person on an as-converted to common stock basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F3 · derivative.underlying_shares: Reflects the number of shares of Preferred Stock held by the Reporting Person on an as-converted to common stock basis. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:25 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionCommon Stock | 1,013,547 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-047457 · a4.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,453,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 21:25 UTC | Replimune Group, Inc. REPL · Entity 4707 | ConversionCommon Stock | 3,439,839 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-047457 · a4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,439,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock and series B convertible preferred stock (collectively, the "Preferred Stock") converted into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment or consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | ConversionSeries B Preferred Stock · Derivative | 3,740,239 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · derivative · entry 6 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 905,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | ConversionSeries A Preferred Stock · Derivative | 12,580,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · derivative · entry 5 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,044,579 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | ConversionSeries Seed Preferred Stock · Derivative | 3,333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · derivative · entry 4 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 806,711 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | ConversionCommon Stock | 905,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,756,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | ConversionCommon Stock | 3,044,579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,851,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | ConversionCommon Stock | 806,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 806,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), upon the conversion of the Issuer's Series Seed Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries B Preferred Stock · Derivative | 204,339 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018342 · doc4.xml · derivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries A Preferred Stock · Derivative | 12,061,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018342 · doc4.xml · derivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,667,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 20:36 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionCommon Stock | 4,746,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018342 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,843,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.